JP2023518414A5 - - Google Patents

Info

Publication number
JP2023518414A5
JP2023518414A5 JP2022556038A JP2022556038A JP2023518414A5 JP 2023518414 A5 JP2023518414 A5 JP 2023518414A5 JP 2022556038 A JP2022556038 A JP 2022556038A JP 2022556038 A JP2022556038 A JP 2022556038A JP 2023518414 A5 JP2023518414 A5 JP 2023518414A5
Authority
JP
Japan
Prior art keywords
antigen
item
virus
scaffold
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518414A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/024023 external-priority patent/WO2020191361A2/en
Application filed filed Critical
Priority claimed from PCT/US2021/023485 external-priority patent/WO2021189047A2/en
Publication of JP2023518414A publication Critical patent/JP2023518414A/ja
Publication of JP2023518414A5 publication Critical patent/JP2023518414A5/ja
Pending legal-status Critical Current

Links

JP2022556038A 2020-03-20 2021-03-22 治療のための細胞外小胞 Pending JP2023518414A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
USPCT/US2020/024023 2020-03-20
PCT/US2020/024023 WO2020191361A2 (en) 2019-03-21 2020-03-20 Extracellular vesicles for vaccine delivery
US202063001088P 2020-03-27 2020-03-27
US63/001,088 2020-03-27
US202063003171P 2020-03-31 2020-03-31
US63/003,171 2020-03-31
US202063006585P 2020-04-07 2020-04-07
US63/006,585 2020-04-07
US202063017514P 2020-04-29 2020-04-29
US63/017,514 2020-04-29
US202163142418P 2021-01-27 2021-01-27
US63/142,418 2021-01-27
PCT/US2021/023485 WO2021189047A2 (en) 2020-03-20 2021-03-22 Extracellular vesicles for therapy

Publications (2)

Publication Number Publication Date
JP2023518414A JP2023518414A (ja) 2023-05-01
JP2023518414A5 true JP2023518414A5 (cg-RX-API-DMAC10.html) 2024-04-16

Family

ID=77771656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556038A Pending JP2023518414A (ja) 2020-03-20 2021-03-22 治療のための細胞外小胞

Country Status (6)

Country Link
US (1) US20250114445A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121450A2 (cg-RX-API-DMAC10.html)
JP (1) JP2023518414A (cg-RX-API-DMAC10.html)
AU (1) AU2021236763A1 (cg-RX-API-DMAC10.html)
CA (1) CA3171623A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021189047A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12357704B2 (en) 2019-05-06 2025-07-15 Thomas Malcolm Tailored hypoimmune nanovesicular delivery systems for cancer tumors
WO2022013609A1 (en) * 2020-07-13 2022-01-20 Immunovaccine Technologies, Inc. Sars-cov-2 vaccine compositions and methods of preparation and use
WO2023056468A1 (en) * 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
JP2024537791A (ja) * 2021-10-01 2024-10-16 グリットストーン バイオ インコーポレイテッド 汎コロナウイルスワクチン
WO2023085821A1 (ko) * 2021-11-10 2023-05-19 주식회사 씨케이엑소젠 엑소좀 기반 항바이러스 백신 및 이의 제조방법
CA3257248A1 (en) * 2022-05-25 2023-11-30 Thomas Malcolm BIOMIMITED HYPOIMMUNE ALLOGENEIC NANOVESICULE FOR CANCER TREATMENT
EP4538381A4 (en) * 2022-07-13 2025-10-22 Univ Ewha Ind Collaboration EXTRACELLULAR VESICLE COMPRISING AN ANTIGENIC PROTEIN OR A GENE ENCODING THIS PROTEIN, AND USES THEREOF
CN120500355A (zh) * 2022-08-17 2025-08-15 隆萨销售股份有限公司 包含生物活性分子和细胞穿透肽可裂解接头的细胞外囊泡
EP4713015A1 (en) * 2023-05-17 2026-03-25 National University of Singapore Surface display of immunotherapeutics on extracellular vesicles and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2004073319A2 (en) * 2003-02-14 2004-08-26 Anosys, Inc. Methods and compounds for raising antibodies and for screening antibody repertoires
AU2004254600A1 (en) 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US20090169576A1 (en) 2005-10-26 2009-07-02 Roberto Crea Influenza combinatorial antigen vaccine
EP2510946B1 (en) 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
WO2009026660A1 (en) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
EP2200639B1 (en) 2007-09-24 2016-03-30 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
EP2486134B1 (en) 2009-10-06 2014-01-08 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
KR101866893B1 (ko) 2010-10-01 2018-06-14 벤티알엑스 파마슈티칼스 인코포레이티드 Tlr 아고니스트의 치료적 용도 및 병용 요법
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
WO2013053008A2 (en) 2011-10-14 2013-04-18 The Walter And Eliza Hall Institute Of Medical Research Molecules which bind clec9a
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
DK3233882T3 (da) 2014-12-16 2020-01-27 Kayla Therapeutics Fluorinerede cykliske dinukleotider til cytokininduktion
EP3233191A1 (en) 2014-12-16 2017-10-25 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
US11066453B2 (en) * 2015-05-18 2021-07-20 Biomvis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
KR20240033086A (ko) 2017-08-25 2024-03-12 코디악 바이오사이언시즈, 인크. 막 단백질을 사용한 치료용 엑소좀의 제조
US20190151456A1 (en) 2017-11-17 2019-05-23 Codiak Biosciences, Inc. Compositions of Engineered Exosomes and Methods of Loading Luminal Exosome Payloads
EP3731849A4 (en) * 2017-12-28 2021-12-01 Codiak BioSciences, Inc. EXOSOME FOR IMMUNONCOLOGICAL AND ANTI-INFLAMMATORY THERAPY
TW202003032A (zh) * 2018-03-23 2020-01-16 美商科迪亞克生物科學公司 包含s t i n g 促效劑之胞外囊泡
EP4059510B1 (en) 2018-11-16 2025-05-21 Lonza Sales AG Engineered extracellular vesicles and uses thereof
WO2020191361A2 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery

Similar Documents

Publication Publication Date Title
JP7863957B2 (ja) 新規な人工核酸分子
Li et al. Rational design of T-cell-and B-cell-based therapeutic cancer vaccines
US20180179553A1 (en) Compositions and methods for nucleic acid and/or protein payload delivery
CN109937253A (zh) 高纯度rna组合物及其制备方法
US20130253168A1 (en) Novel single chemical entities and methods for delivery of oligonucleotides
US20190167809A1 (en) METHODS OF TREATING A SUBJECT WITH mRNA ENCODING COAGULATION FACTOR VIII (F8)
US20040146948A1 (en) Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
RU2017138373A (ru) Праймирование иммунного ответа
CN109563537B (zh) 使用核酸适体用于导向的模板化组装的方法
JP6518193B2 (ja) 改善された特性を有する改変コイルドコイル型タンパク質
US20200149070A1 (en) Methods and compositions for genome editing
US20200208177A1 (en) Methods and compositions for genome editing
TWI354023B (en) Lipidating sequences and use thereof for producing
AU2024255035B2 (en) Methods and compositions for targeted delivery by polymersomes
JP2024516613A5 (cg-RX-API-DMAC10.html)
JP2022517236A (ja) 自己組織化ペプチドナノ粒子およびその使用
JP2023521722A5 (cg-RX-API-DMAC10.html)
CA2443644A1 (en) Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
WO2022141771A1 (zh) 一种长效化白介素15融合蛋白及其制备方法和应用
JP2024069465A5 (cg-RX-API-DMAC10.html)
EP4110384A2 (en) Compositions comprising self-assembling vaccines and methods of using the same
JP2025521199A (ja) 有効成分の標的送達のための脂質マイクロバブル
US20250074966A1 (en) Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis
CN120349423A (zh) 用于诱导免疫反应及治疗癌症的融合蛋白
JP2024540322A5 (cg-RX-API-DMAC10.html)